CuraGen Licenses TopoTarget’s HDAC Inhibitor
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 49 (Table of Contents)
Published: 4 Jul-2004
DOI: 10.3833/pdr.v2004.i49.798 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
CuraGen acquired exclusive rights to develop and commercialise TopoTarget’s PXD101 (Phase I treatment for solid and hematological cancers) in Europe. TopoTarget will receive more than US$51 M for PDX101 and reciprocal royalties from CuraGen...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS